2025.03.26

Genomtec implements changes in organizational structure to accelerate M&A process

Genomtec SA has established two special purpose vehicles, GMT ID SA and GMT Genomics SA, in which it holds 100% of the shares. They will receive ...
2025.03.12

The company will obtain approximately PLN 11 million from the issue to support the commercialization of projects

The shareholders of Genomtec SA at the Extraordinary General Meeting on 12 March 2025 voted on a resolution to increase the Company’s share ...
2025.02.12

Genomtec to issue shares to raise funds to support commercialization of projects

The company’s shareholder – 5HT FR intends to sell 1.3 million existing shares of the company in a public offering and use the entire ...
2025.01.28

Genomtec has filed a second patent application for the OncoSNAAT oncology project

Genomtec SA announced today that it has filed a patent application with the British Patent Office for an innovative technology for the diagnosis ...
2024.06.25

Webinar: Trends in the M&A Market Specific to In-Vitro Diagnostics | 27 June, 2024, 3:00 p.m. (CEST)

Dear Investors GENOMTEC S.A. invite you to an investor webinar discussing the market in which the company operates and trends in the M&A ...
2024.04.22

Dr. Trevor Hawkins, a distinguished entrepreneur, scientist, and leader with experience in global healthcare companies, has joined the Supervisory Board of Genomtec S.A.

Genomtec S.A., announces that the Extraordinary General Meeting of Shareholders of the company appointed Dr. Trevor Hawkins to the Supervisory ...